First vaccine to protect older adults from respiratory syncytial virus (RSV) infection

21 April 2023 – The European Medicines Agency (EMA) has recommended a marketing authorisation in the European Union (EU) for Arexvy (recombinant, adjuvanted), the first vaccine for active immunisation to protect adults aged 60 years and older against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV).

For more information, see here.